XML 29 R18.htm IDEA: XBRL DOCUMENT v3.26.1
Business Concentrations
 3 Months Ended
Mar. 31, 2026
Business Concentrations [Abstract]  
Business concentrations

12. Business concentrations

 

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, we changed our business to become a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. As part of the transformation that included the Mayne License Agreement, all results associated with former commercial operations have been reflected as discontinued operations in our condensed consolidated financial statements. Liabilities associated with the commercial business are classified as liabilities of discontinued operations in our condensed consolidated balance sheets. Additional disclosures regarding discontinued operations are provided in Note 2.

For the three months ended March 31, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.

 

As of March 31, 2026, we had a royalty receivable of $3,211 thousand relating to the short-term portion of receivable from Mayne Pharma, Theramex and Knight and $13,170 thousand relating to the long-term portion of royalty receivable which includes royalties recognized from the minimum annual royalty that Mayne Pharma is obligated to pay to us under the Mayne License Agreement.